Peptide synthesis sales will strengthen through 2036, anchored by reagents at a 46.0% share of the leading product segment in 2026. The market is valued at USD 0.7 billion in 2026 and is forecast to reach USD 1.4 billion by 2036 as peptide therapeutic pipelines expand across research settings.